Genetics, epidemiology, prevention, and early detection of colorectal cancer

Current Opinion in Gastroenterology

Volumn 13, Issue 1, 1997, Pages 5-10

  Hecht, J Randolph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CANCER SCREENING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; FAMILIAL CANCER; GENETICS; HUMAN; POLYMERASE CHAIN REACTION; SHORT SURVEY;

EID: 0031001913     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199701000-00002     Document Type: Short Survey

References (69)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Nakamura Y, White R: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
2. Nagase H, Miyoshi Y, Horii A, Aoki T, Ogawa M, Utsunomiya J, Baba S, Sasazuki T, Nakamura Y: Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992, 52:4055-4057.
3. Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B, et al.: Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993, 75:951-957.
4. van der Luijt RB, Vasen HF, Tops CM, Breukel C, Fodde R, Meera Khan P: APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet 1995, 96:705-710.
5. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch PM, Jenkins JX, Rouse J, Cavalieri J, Howard L, Lynch J: Hereditary flat adenoma syndrome: a variant of familial adenomatous polyposis? Dis Colon Rectum 1992, 35:411-421.
6. Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavalieri J, Lynch J, Slominski-Castor, Cayouette MC, Priluck I, Luce MC: Attenuated familial adenomatous polyposis (AFAP): a phenotypically and genotypically distinctive variant of FAP. Cancer 1995, 76:2427-2433.
7. Iwama T, Mishima Y, Utsunomiya J: The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs: its rational treatment. Ann Surg 1993, 217:101-108.
8. Vasen HF, van der Luijt RB, Slors JF, Buskens E, de Ruiter P, Baeten CG, Scheuten WR, Oostvogel HJ, Kuijpers JH, Tops CM, Meera Khan P: Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996, 348:433-435. Authors bring up the possibility of using molecular information to guide surgical management of FAP.
9. Giardiello FM, Offerhaus JA, Tersmette AC, Hylind LM, Krush AJ, Brensinger LD, Booker SV, Hamilton SR: Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996, 38:578-581.
10. Lynch HT, Thorson AG, Smyrk T: Rectal cancer after prolonged sulindac chemoprevention: a case report Cancer 1995, 75:936-938.
11. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H: Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment: advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995, 38:813-830. Sulindac suppositories result in the disappearance of rectal polyps in patients with FAP and ileorectal anastomoses.
12. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould K, Dove WF: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992, 256:668-670.
13. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM: The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995, 81:957-966.
14. Sanabria JR, Croxford R, Berk TC, Cohen Z, Bapat BV, Gallinger S: Familial segregation in the occurrence and severity of periampullary neoplasms in familial adenomatous polyposis. Am J Surg 1996, 171:136-140.
15. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-1038.
16. Boland CR: Roles of the DNA mismatch repair genes in colorectal tumorigenesis. Int J Cancer 1996, 69:47-49.
17. Chung DC, Rustgi AK: DNA mismatch repair and cancer. Gastroenterology 1995, 109:1685-1699. This is a good review of the DNA mismatch repair system and its relationship to colon cancer syndromes.
18. Reitmair A, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A, Liu B. et al.: MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995, 11:64-70.
19. Reitmair AH, Redston M, Cai JC, Chuang TC, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B, Mak TW: Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 1996, 56:3842-3849.
20. Edelmann W, Cohen PE, Kane M, Lau K, Morrow B, Bennett S, Umar A, Kunkel T, Cattoretti G, Changanti R, et al.: Meiotic pachytene arrest in MLH1-deficient mice. Cell 1996, 85:1125-1134.
21. Leach FS, Polyak K, Burrell M, Johnson KA, Hill D, Dunlop MG, Wyllie AIL, Peltomaki P, de la Chapelle A, Hamilton SR, et al.: Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996, 56:235-240.
22. Wilson TM, Ewel A, Duguid JR, Eble JN, Lescoe MK, Fishel R, Kelley MR: Differential cellular expression of the human MSH2 repair enzyme in small and large intestine. Cancer Res 1995, 55:5146-5150.
23. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Cavalieri R, Boland CR, et al.: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993, 104:1535-1549.
24. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993, 71:677-685.
25. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J: Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996, 77:1836-1843.
26. Albano WA, Recabaren JA, Lynch HT, Campbell AS: Natural history of hereditary cancer of the breast and colon. Cancer 1982, 50:360-363.
27. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP: Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996, 110:682-687.
28. Luce MC, Marra G, Chauhan DP, Laghi L, Carethers JM, Cherian SP, Hawn M, Binnie CG, Kam-Morgan LN, Cayouette MC, et al.: In vitro transcription/translation assay for the screening of hMLH1 and hMSH2 mutations in familial colon cancer. Gastroenterology 1995, 109:1368-1374. The authors discuss the in vitro transcription-translation assay-based test for HNPCC. The assay identifies mutations in the two most commonly altered DNA mismatch repair genes by synthesizing the protein product and looking for truncation. The place for this test in clinical medicine remains to be determined.
29. Luce MC, Binnie CG, Cayouette MC, Kam-Morgan LN: Identification of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer patients. Int J Cancer 1996, 69:50-52.
30. Brentnall TA, Rubin CE, Crispin D, Stevens A, Batchelor RH, Haggitt RC, Bronner MP, Evans JP, McCahill LE, Bilir N, et al.: A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995, 109:151-155.
31. Brentnall TA, Crispin DA, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC, Borland CR: Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996, 56:1237-1240.
32. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996, 2:461-462.
33. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995, 222:695-699.
34. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994, 54:4726-4728.
35. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 1996, 77:1736-1740.
36. Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW: Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 1988, 319:533-537.
37. St. John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES: Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993, 118:785-790.
38. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC: A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994, 331:1669-1674.
39. Levin B, Murphy GP: Revision in American Cancer Society recommendations for the early detection of colorectal cancer. CA Cancer J Clin 1992, 42:296-299.
40. Ponz de Leon M, Antonioli A, Ascari A, Zanghieri G, Sacchetti C: Incidence and familial occurrence of colorectal cancer and polyps in a health-care district of northern Italy. Cancer 1987, 60:2848-2859.
41. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M, Panish JF, et al.: Risk of colorectal cancer in the families of patients with adenomatous polyps: National Polyp Study Workgroup. N Engl J Med 1996, 334:82-87.
42. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983, 24:83-87.
43. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P. Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316.
44. Thun MJ, Namboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596.
45. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121:241-246.
46. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971, 231:232-235.
47. Kujubu DA, Fletcher BS, Varum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866-12872.
48. DuBois RN, Radhika A, Reddy BS, Entingh AJ: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996, 110:1259-1262.
49. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
50. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
51. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD: G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996, 56:733-737.
52. Shift SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995, 96:491-503.
53. Schnitzler M, Dwight T, Robinson BG: Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Gut 1996, 38:707-713.
54. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, et al.: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996, 56:2556-2560.
55. Alberts DS, Hixson L, Ahnen D, Bogert C, Einspahr J, Paranka N, Brendel K, Gross PH, Pamukcu R, Burt RW: Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 1995, 22:18-23.
56. Screening for colorectal cancer: United States, 1992-1993, and new guidelines. MMWR Morbid Mortal Wkly Rep 1996, 45:107-110. For years the US Preventive Services Task Force has refused to recommend colorectal cancer screening due to what it considered insufficient data. They finally backed the use of annual fecal occult blood testing or periodic flexible sigmoidoscopy (or both) beginning at age 50.
57. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365-1371.
58. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992, 326:653-657.
59. Thomas WM, Hardcastle JD, Jackson J, Pye G: Chemical and immunological testing for faecal occult blood: a comparison of two tests in symptomatic patients. Br J Cancer 1992, 65:618-620.
60. St. John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC: Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993, 104:1661-1668.
61. Allison JE, Tekawa IS, Ransom LJ, Adrain AL: A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med 1996, 334:155-159.
62. Foliente RL, Wise GR, Collen MJ, Abdulian JD, Chen YK: Colocare self-test versus Hemoccult II Sensa for fecal occult blood testing. Am J Gastroenterol 1995, 90:2160-2163.
63. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992, 256:102-105.
64. Nollau P, Moser C, Wagener C: Isolation of DNA from stool and bodily fluids for PCR amplification. Biotechniques 1996, 20:784-787.
65. Eguchi S, Kohara N, Komuta K, Kanematsu T: Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996, 77(suppl 8):1707-1710.
66. Yoshida K, Sugino T, Bolodeoku J, Warren BF, Goodison S, Woodman A, Toge T, Tahara E, Tarin D: Detection of exfoliated carcinoma cells in colonic luminal washings by identification of deranged patterns of expression of the CD44 gene. J Clin Pathol 1996, 49:300-305.
67. Vining DJ: Virtual endoscopy: is it reality? Radiology 1996, 200:30-31.
68. Hara AK, Johnson CD, Reed JE, Ahlquist DA, Nelson H, Ehman RL, et al.: Detection of colorectal polyps by computed tomographic colography: feasibility of a novel technique. Gastroenterology 1996, 110:284-290. This is the largest published report on virtual colonoscopy from a group with one of the largest experiences.
69. Hara AK, Johnson CD, Reed JE, Ehman RL, Ilstrup DM: Colorectal polyp detection with CT colography: two- versus three-dimensional techniques. Work in progress. Radiology 1996, 200:49-54. This is the largest published report on virtual colonoscopy from a group with one of the largest experiences.